Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
αFAP-IR700
- Development stage
- Preclinical
- Modality
- Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
αFAP-IR700 is a **monoclonal antibody-drug conjugate** consisting of an anti-fibroblast activation protein (FAP) antibody covalently linked to the near-infrared photosensitizer IRDye700DX (IR700). It is used in **near-infrared photoimmunotherapy (NIR-PIT)** to target and eradicate **cancer-associated fibroblasts (CAFs)** in solid tumors, particularly **pancreatic ductal adenocarcinoma (PDAC)**. Upon binding to FAP on CAFs, exposure to near-infrared light induces rapid cell death via photo-induced physical membrane damage and immunogenic cell death (ICD), leading to a reduction of tumor stroma and potentially enhancing antitumor immune responses and the efficacy of chemotherapy[1]. Primary indication: preclinical studies in **pancreatic ductal adenocarcinoma** (PDAC)[1].
- Brand names
- αFAP-IR700
- Other names
- anti-FAP-IR700anti-FAP-IR-700anti-FAP-IR 700anti-fibroblast activation protein antibody-IRDye700DX conjugate
02
Targets
FAP (Fibroblast activation protein alpha)
Beyond the preview
Go deeper on αFAP-IR700.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on αFAP-IR700.